[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thrombosis-artery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thrombosis-artery":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100629166","phase-3-switch-apixaban-vs-vitamin-k-in-hm3-100629166",false,"NCT07471139","SWITCH: Apixaban vs Vitamin K in HM3","The SWITCH Trial: A Randomized Controlled Study of Apixaban Versus Vitamin K Antagonists in Patients With HeartMate 3 Left Ventricular Assist Devices","Inclusion Criteria:\n\n* Participants will have HeartMate3 LVAD implanted \\> 3 months before enrollment\n* ≥ 18 years old\n* Treated with WARFARIN SODIUM\n* Participant must provide written informed consent prior to any clinical investigation related procedure\n* In female participants of childbearing capability, not currently pregnant and on appropriate contraception\n\nExclusion Criteria:\n\n* Participation in any other clinical investigation(s) involving a Mechanical Circulatory Support (MCS) device, or interventional investigation(s) likely to confound study results or affect study outcome\n* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results\n* Known allergy to Apixaban\n* Bridge to transplant\n* Severe renal dysfunction Estimated Glomerular Filtration Rate (eGFR) \\\u003C20\n* History of major bleeding event with subsequent reduction of INR goal to \\\u003C 1.8\n* Apixaban dose reduction criteria (Age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg\u002FdL)\n* Aortic root thrombus","ALL","18 Years","80 Years",{"count":20,"type":21},460,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.",[27,28,29,30,31,32],"LVAD (Left Ventricular Assist Device) Thrombosis","Heart Failure","Bleeding","Thrombosis; Artery","Stroke","Heart Transplant","NOT_YET_RECRUITING","2026-03-11",{"date":36,"type":37},"2026-03-13","ACTUAL",{"date":39,"type":21},"2026-06",{"date":41,"type":21},"2029-06",{"name":43,"class":44},"Columbia University","OTHER"]